.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AJ04_Cabotegravir.Cabotegravir_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AJ04_Cabotegravir.Cabotegravir_1| name: | Cabotegravir_1 |
| ATC code: | J05AJ04_1 | route: | intramuscular |
| n-compartments | 2 |
Cabotegravir is a long-acting integrase strand transfer inhibitor (INSTI) used for the treatment and prevention of HIV-1 infection in adults and adolescents. It is approved for use in combination with rilpivirine for both treatment and pre-exposure prophylaxis (PrEP).
Pharmacokinetics following a single 400 mg intramuscular injection in healthy adults.
Han, K, et al., & Ford, SL (2024). Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV. Antimicrobial agents and chemotherapy 68(12) e0088024–None. DOI:10.1128/aac.00880-24 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39440971
Thoueille, P, et al., & Guidi, M (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. Clinical pharmacology and therapeutics 115(6) 1450–1459. DOI:10.1002/cpt.3240 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38519844
Han, K, et al., & Ford, SL (2022). Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. British journal of clinical pharmacology 88(10) 4607–4622. DOI:10.1111/bcp.15439 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35695476